Tropicamide
As of the edition of 20 October 2026, Tropicamide is a small molecule: marketed, first approved in 1951 (CA); acts on CHRM3.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2013
- Kind
- Small molecule
- Brand name
- Mydriacyl
- First approved
- 31 December 1951 (CA)
- Approvals on record
- 13 in 6 regions
- Holder of the most recent approval
- Eyenovia; 7 holders in all
- Registered trials
- 19, 1 stopped early
- Disease areas
- Eye; Nervous system; Heart and blood vessels; Hormones; Inherited and neonatal; Chemically induced
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
1 company on route B because of this drug.
Companies on route B for this drug
In the product1 company is on route B because of Tropicamide.
See the 1 company on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| CHRM3 | Muscarinic acetylcholine receptor M3 | P20309 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 8 | 4 | 1 | 1 |
| Phase 1 | 1 | 1 | 0 | 0 |
| Phase 2 | 1 | 1 | 0 | 0 |
| Phase 3 | 2 | 2 | 0 | 0 |
| Phase 4 | 7 | 5 | 0 | 0 |
| All trials | 19 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Alcon | Applicant | 1951 to now |
| Bausch Health | Later holder | 1995 to now |
| Thea Pharma | Applicant | 1999 to now |